STERIS plc (STE) Earnings Call Transcript & Summary
November 5, 2026
What were the key takeaways from STERIS plc's November 5, 2026 earnings call?
In the second quarter of fiscal 2027, STERIS plc reported total revenue of $1.6 billion, reflecting a 9% year-over-year growth. Adjusted earnings per share (EPS) increased 19% to $2.94, driven by tariff refunds and operational efficiencies. Management raised their EPS guidance for the fiscal year to a range of $11.35 to $11.55, up from the previous range of $11.10 to $11.30, indicating strong performance and confidence in future growth despite some segment-specific challenges.
What topics did STERIS plc cover?
- Revenue Growth: Total revenue grew 9% to $1.6 billion, with constant currency organic revenue up 8%. Management noted, "Our performance reflected solid underlying demand with continued strength in our GI business."
- Margin Expansion: Adjusted gross margin improved to 45.3%, up 100 basis points year-over-year, primarily due to tariff refunds of approximately $20 million. Burton stated, "Margin expansion was driven primarily by tariff refunds..."
- Acquisition of Xodus Medical: The acquisition is expected to enhance STERIS's consumables offering and provide a new call point in operating rooms. Carestio expressed excitement, stating, "This highly clinical, single-use portfolio will strengthen our recurring revenue..."
- Guidance Update: Management updated their fiscal 2027 EPS guidance to $11.35 to $11.55, citing strong second quarter performance. Carestio noted, "The additional increase in outlook was driven by second quarter outperformance and lower interest."
- Healthcare Segment Performance: Healthcare constant currency organic revenue grew 7%, with service revenue up 10%. However, EBIT margins decreased by 110 basis points to 24%, impacted by inflation and lower productivity. Carestio mentioned, "Improvements in volume and price were more than offset by inflation..."
What were STERIS plc's November 5, 2026 results?
- Total Revenue: $1.6 billion (+9% YoY)
- Adjusted EPS: $2.94 (+19% YoY)
- Adjusted Gross Margin: 45.3% (+100 basis points YoY)
- Healthcare Revenue Growth: 7%
- Life Sciences Revenue Growth: 18%
- AST Revenue Growth: 5%
Overall, STERIS's strong revenue growth and improved EPS guidance are positive indicators for the investment thesis. However, challenges in the AST segment and the need for ongoing restructuring may pose risks. Investors should monitor the integration of the Xodus Medical acquisition and the performance of the healthcare and life sciences segments in the coming quarters.
Earnings Call Speaker Segments
Julie Winter
executiveThank you, Nick, and good morning, everyone. On today's call, we'll be hearing from Karen Burton, our Senior Vice President and CFO, along with Dan Carestio, our President and CEO. Before we open things up for comments from management, I do want to offer a few words of caution. The information in this webcast is time-sensitive and accurate only as of today. Redistributing, retransmitting, or rebroadcasting this call in any form without STERIS's express written consent is strictly prohibited. Certain statements made during this review are, or may be considered, forward-looking statements. There are various significant elements that might lead actual outcomes to vary materially from what the forward-looking statements anticipate, such as, but not restricted to, the risk factors outlined in STERIS' securities filings. The company makes no commitment to update or revise any forward-looking statements because of new information, future events, or developments. STERIS' SEC filings can be obtained from the company and through our website. Additionally, non-GAAP financial measures will be referenced on today's call, among them adjusted earnings per diluted share, adjusted operating income, constant currency organic revenue growth, and free cash flow. Further details regarding these measures, including definitions, can be found in our release, along with reconciliations between GAAP and non-GAAP financial measures. On this call we’ll present non-GAAP financial measures because we want to give you more visibility into the additional financial information that management and the board of directors rely on when analyzing finances and making operational decisions; with those caveats noted, I’ll now turn things over to Karen.
Karen Burton
executiveThank you, Julie, and good morning to all of you. I'm glad to join you today to walk through the key points from our second quarter results. In Q2, total revenue on an as-reported basis rose 9%, reaching $1.6 billion. Organic revenue in constant currency climbed 8% during the quarter, with volume and 230 basis points of price both contributing. Adjusted gross margin came in at 45.3% for the quarter, 100 basis points higher than a year earlier. The main driver of that margin expansion was roughly $20 million of tariff refunds received in the quarter, which contributed 130 basis points year-over-year. Underlying margins slipped modestly, since inflation more than outweighed the benefit of favorable price. Gross tariff costs were about $15 million in Q2, unchanged from the prior year. To be clear, we are not allocating tariff refunds to our business segments; they are recorded at corporate instead, which allows for business segment analysis. Adjusted EBIT margin for the quarter was 24.6%, an increase of 150 basis points versus the second quarter of last year. Tariff refunds accounted for 130 basis points of that gain. The underlying margin improvement came from favorable price and volume, partly offset by inflation and business investments, among them the acceleration of R&D spending. We don't anticipate any material tariff refunds beyond these for the rest of fiscal 2027. The adjusted effective tax rate was 25.3% in the quarter, up from 24.5% in last year's second quarter. That rise was mainly due to unfavorable discrete items. Adjusted net income for the quarter totaled $286.8 million, versus $244.5 million a year ago. Adjusted earnings per share came to $2.94, up 19% from $2.47 in the second quarter of last year. If you exclude tariff refunds, adjusted earnings per diluted share rose 13%. Capital expenditures in Q2 were $76.1 million, while depreciation and amortization came to $125.6 million. We closed the quarter with a strong balance sheet, carrying $1.9 billion of total debt. Gross debt to EBITDA at quarter end stood at roughly 1.1 times. Free cash flow for the first six months was $492.5 million, down from $527.7 million in the same period a year earlier. Cash flow from operations was $656.1 million, compared with $707.8 million last year. The decrease in cash flow was mainly due to a much smaller working capital contribution, as we used cash to build inventory ahead of second-half shipments, partly offset by higher net income. Share buybacks totaled $100 million in the second quarter, or $200 million year-to-date. We have $800 million left under our current authorization. During the quarter, we approved an additional restructuring plan covering targeted facility realignment, product rationalization, and select organizational realignment; we expect total charges of $45 million, including $10 million in cash expenditures and $35 million in non-cash charges. Approximately $25 million was recorded in the second quarter. We expect this plan to produce roughly $9 million in annualized savings, with some of that coming through in fiscal 2028 and the complete benefit arriving in later fiscal years; that said, I'll hand things over to Dan now for his remarks.
Dan Carestio
executiveThank you, Karen, and hello everyone on this morning's call. We're glad you could be with us as we walk through our results for Q2 of 2027 and share our outlook for the remainder of the year. Since Karen already covered the quarter's headline figures, I'll add some perspective on our business segments. Starting with Healthcare: organic revenue at constant currency rose 7% during the quarter. Those results showed healthy underlying demand, and our GI business kept up its momentum. Thanks to the strength of our portfolio and our commercial teams, we're able to guide customers through a complicated operating landscape. Service extended its run of standout performance, posting 10% growth in the second quarter. Consumables were up 10%, helped by higher customer consumption and fueled by share gains, procedure growth in endoscopy, and, to a smaller degree, a recent acquisition of GI products. Revenue from healthcare capital equipment climbed 4% for the quarter, also getting a lift from a recent acquisition. Orders held steady, growing 1% in the second quarter, and our ending backlog grew to $456 million. EBIT margins in Healthcare fell 110 basis points to 24% for the quarter. Gains in volume and price were outweighed by inflation, weaker productivity, and longer-term investments we sped up thanks to tariff refunds. Now moving to AST: organic revenue in constant currency rose 5% this quarter, and services were up 5% as reported—6% on a constant currency basis. We closed the quarter in a strong position, and early signals indicate October is sustaining that momentum. AST's EBIT margin came in at 44.7%, roughly 60 basis points lower than the second quarter of last year. That drop was driven by higher depreciation and inflation, partly offset by better pricing. For Life Sciences, constant currency organic revenue was up 18% this quarter. Fueling that: capital equipment climbed 53% and consumables rose 9%. Service revenue increased 5%. Backlog stood at $93 million at quarter end, reflecting robust shipments and a modest decline versus the prior year. We achieved a record margin of 44.4%, up roughly 310 basis points, driven by gains in volume, price, productivity, and a favorable mix. Our Life Sciences segment is benefiting from reshoring and the localization of manufacturing. Before moving to the outlook, I want to cover the agreement we announced recently to acquire Xodus Medical, a surgical specialties products business focused on patient and OR staff safety. Xodus Medical is a natural fit alongside our Healthcare portfolio, extending our consumables offering and how we support customers in the operating room. The business is well-known for its flagship Pink Pad, a single-use surgical patient positioning product, though its portfolio is much broader. The company's offerings cover positioning of patients, handling and moving patients, warming patients, and OR essentials. This portfolio—highly clinical and single-use—will reinforce recurring revenue and broaden our direct commercial footprint in the operating room. Growth at Xodus has been consistently impressive, powered by a steady flow of innovation and a very effective commercial model. Under our go-forward model, we maintain revenue growth in the mid-teens along with EBIT margins in the low to mid-50%s. Backed by clinical research, AORN guidance, a robust innovation pipeline, and intellectual property protections for our core products, our competitive clinical position is unambiguous. As our companies join forces to serve customers better, we are genuinely excited about what lies ahead. Now for the forecast: based on what we delivered in Q2 and our expectations for the remainder of the year, we are updating our fiscal 2027 guidance. We still see the same overall company revenue growth, which includes as-reported growth of 7%-8% and constant currency organic growth of 6%-7%. For fiscal 2027, earnings per diluted share are now projected at $11.35 to $11.55, up from the earlier range of $11.10-$11.30. That figure reflects an approximate $0.18 per share gain from tariff refunds received so far in fiscal 2027. The rest of the raise stems from our stronger-than-expected second quarter performance and reduced interest. By segment, Healthcare constant currency organic revenue growth remains expected at 6%-7%. Regarding AST, our forecast is now 6%-7% growth, a reduction from the 7%-8% range we had earlier projected. This adjustment assumes we sustain the exit rate from quarter two through the remainder of the year. Because of an outstanding first half, we are lifting the constant currency organic growth outlook for Life Sciences to 9%-10% from the prior 6%-7%; that increase mirrors a shift back toward more typical growth during the latter six months, along with first half outperformance driven by capital equipment. All other components of the outlook we shared most recently remain the same, but please note that outlook does not include Xodus Medical, and we will refresh our expectations once the deal closes. This is genuinely an exciting time at STERIS. Operations are delivering strong results, which lets us direct funding toward initiatives that will underpin expansion well into the future. My thanks go out to every one of our associates, who keep concentrating on customers and working to improve a bit every single day. That wraps up the prepared portion of today's call. Nick, please go ahead with the instructions so we can open the Q&A.
Brett Fishbin
analystHey, everyone. Thanks a lot for taking my questions, and good morning. Perhaps I'll start with the Xodus Medical acquisition — it really does look like a strong fit for STERIS, and I was wondering if you could say a little more beyond what you've already shared about why this one was especially appealing for the company, and then, more broadly, how you're viewing this new call point as a longer-term opportunity for the Healthcare business.
Dan Carestio
executiveThanks, Brett. I appreciate the question; we're very excited about the planned acquisition of Xodus. As you said, this provides us with an additional point of contact and an actual clinical sales team inside the OR, something we genuinely lack at present. I mean, our surgical infrastructure, capital equipment, lights and tables, and ORI are sold more through a construction-oriented, architectural-style approach. What this really does is give us a daily reason to be present in the operating room—which, depending on your perspective, marks either the start or the finish of reprocessing within the full perioperative cycle. Their product lineup is excellent. These items carry high margins, show strong growth, are consumable, and have delivered an impressive performance trajectory for roughly seven or eight years now. This product is seeing strong adoption and positive feedback from customers. AORN backs it, and we believe it will be a valuable addition for STERIS.
Brett Fishbin
analystAll right. Great, great; so perhaps only one further question regarding the guidance. I believe the AST topic has, or pardon me, the Applied Sterilization Technologies topic has been somewhat of a discussion point, and a competitor of yours mentioned certain incremental headwinds in Europe related to general activity levels. So I was wondering whether the adjustment to guidance, that minor adjustment to guidance, stems more from ongoing inventory dynamics or whether you're likewise observing some kind of deceleration or softening in any specific geographies. Thank you very much.
Dan Carestio
executiveCertainly, Brett. Here's what I'd say. We got off to a sluggish start this year owing to really tough comps. As we moved into Q2, which has just wrapped up, obviously, we saw that get better, particularly in September, and those gains carried on through October. So we're fairly confident about the back half that we'll land somewhere in the 6%-8% growth for that side of the business; the numbers we've seen so far back that up. I wouldn't say there's a reason. In fact, we obviously do pay attention to the others' reports, and we actually posted better growth, or growth as good or better, in Europe last quarter than we did in North America; so, I think it's simply pockets of different customers and things that occur that cause some of this. So I wouldn't read too much into that. Regarding general volume in the U.S., we've mentioned this previously, we expect it to be procedural growth at the lower end of the range, which is roughly 3% rather than the high end of that range, which can be 5%, which drives consumption across all of our businesses for the most part.
Brett Fishbin
analystOkay, thanks again — I really appreciate it.
Dan Carestio
executiveYes.
Patrick Wood
analystGreat, thank you. Perhaps on the first question, to return to AST once more: as volumes begin recovering, roughly or qualitatively, where do we stand on utilization? EO is surely quite tight, but clearly items such as gamma, the half-life fixed costs beyond that—there's a lot of discussion as volumes start returning and flowing through the P&L to margins. So will we see, as volumes recover, some leverage coming through on those facilities? I'm unsure where utilization stands now relative to history. Thanks.
Dan Carestio
executiveYes, thanks, Patrick. Dan here. Utilization overall across the network is quite high, yet effectively we have space everywhere, since volumes are a bit less aggressive than what we expected at the start of the year. As volumes return onto the existing infrastructure we have in place and the capacity we've installed—because we never slowed our isotope loading or anything of that sort, since if you miss it, you miss it forever—so we've maintained our loadings. We have sufficient capacity to absorb the added demand as it comes through. Yes, you're right. A difference of a couple percentage points makes an awfully large difference when it comes to drop-through at the margin line. Part of that is offset by some new facilities being in ramp-up mode, so those obviously aren't contributing margin at the same level as a very mature facility; so that has a somewhat dilutive effect, but those are, for the most part, already in the P&L, and any volume improvement should show through.
Patrick Wood
analystCrystal clear. Thanks. So just quickly then, regarding the Healthcare business — sure, of the capital equipment line, a large portion is basically non-optional, clearly, since you're going to have to be sterilizing. But some of it is a bit more surgically tied in on that side. Maybe this is a little off the beaten path, but the 340B reform rules seemed like they got finalized last night. We're all debating what impact that might have on hospitals, or on those hospitals' P&Ls that were leaning on it somewhat. I don't know. Have you picked up anything from customers regarding their CapEx outlook, whether that would impact them, or is it just more of the same?
Dan Carestio
executiveJust more of the same. Actually, we had a really strong order quarter on our surgical products this past quarter. There's a bit of a shift happening in Healthcare today, where the plan is, as our population ages here domestically at least, hospitals will have to push healthy patients out to their ASC networks for procedures, and they'll have to bring higher acuity patients into the large acute care facilities, which will require more capacity at those locations; so we haven't seen any slowdown on the capital at all. Our Healthcare backlog is pretty much near record if you exclude the supply chain crisis a few years ago; but so we feel pretty good about that.
Patrick Wood
analystAppreciate it, Dan. I'll stop talking now.
Dan Carestio
executiveRight. Thank you, Patrick.
Mac Etoch
analystHey, good morning, and thanks for taking my questions. Perhaps we could begin with the Life Sciences segment. You said before that onshoring might be more of a longer-term benefit, but based on some of your prepared remarks, could you elaborate on what you're seeing today and how you're thinking about how some of these broader macro factors are developing compared with maybe at the start of the year?
Dan Carestio
executiveYes. I think what's different today is that some of the plans our customers previously announced for expansion in the U.S., and also some of the juxtaposition of manufacturing in Europe, were just that, but now they're starting to materialize, and we're starting to see orders from a capital equipment perspective; also, we're starting to see requests for work on our chemistry side of the business as well. Having said that, this past quarter was the outperformance there. We had a great order shipments quarter, but one particular order really made a big difference that was in excess of $10 million for a single customer. So, that one moved the needle. That one won't be replaced on a quarterly basis. Nonetheless, we expect great performance by Life Sciences throughout the end of the year.
Mac Etoch
analystUnderstood, and thank you for that. So perhaps we could briefly turn to tariffs too. I believe you mentioned $24 million as the overall amount of tariff refunds available for the year. Has that figure changed in any way? Has the pool of available refunds gotten bigger? I realize nothing extra is being baked into the guidance, obviously, but I'd just like to get a feel for it.
Karen Burton
executiveThanks, Mac. This is Karen speaking. The $24 million in tariffs we've received is what we anticipate receiving. The IEEPA tariffs we paid last year totaled $27 million, so roughly $3 million of that has no refund program in place at present through which to recover it, which means we aren't projecting that we'll receive those funds.
Mac Etoch
analystThank you for taking my questions.
Dan Carestio
executiveOkay.
Mike Polark
analystMorning, and thanks for taking my questions. Dan, I'd like you to help me bridge the growth in Healthcare consumables. I realize a bit of small M&A is flowing through, but 7% last year, and call it solidly high single digits year to date, while AST volumes have been muted — what explains that gap? Why is Healthcare consumables growth levered at a high level, growing at a much higher rate, while AST volumes still seem tempered?
Dan Carestio
executiveThat has a simple explanation, Mike. The fact is, across the past few years, we've put a tremendous amount of dedicated chemistry equipment into the field. That includes items such as V-PROs, our washers, and of course AERs. So those capital-side share gains we've been posting are now turning into growth on the consumables side. On top of that, a big chunk of our chemistries franchise and Healthcare consumables is tied to endoscopy — specifically the chemistry that runs through our automated endoscope reprocessors — and we've had a really strong year so far when it comes to placing new machines. Beyond that, endoscopy's overall growth rate has stayed solid. By overall growth rate, I mean procedures have consistently held in the mid to high single digits. Our Healthcare consumables business does carry somewhat of an endoscopy bias.
Mike Polark
analystLet me pick up on that point. That was simply one of the other subjects I had. Yes, I heard it, just now, and then during your prepared remarks, the enthusiasm about GI was reaffirmed. There's a competitor that's dealing with some difficulties in the U.S. — Olympus, I'll name it so you don't have to. Obviously, scopes aren't what you sell, but reprocessors and perhaps some accessories are what they sell. Has that turned into a benefit worth calling out separately in your GI business, or no, this isn't a share gain, it's pure execution and market?
Dan Carestio
executiveMike, a benefit it has been, but a minor one. Improved AER sales have come over a quarter or two, but there are still an awful lot of those machines out there, I mean. Over time, we'll keep doing well, I'm sure. As I said, a help it has been, but in the grand scheme of things it's been insignificant.
Mike Polark
analystThank you.
Dan Carestio
executiveYep.
Mike Matson
analystYeah, thanks. I just want to ask one more thing about Xodus Medical. Based on our rough math, it looks like this could be a pretty accretive acquisition to EPS. I mean, we're getting to something like 3%-5% EPS accretion on an annual basis. I mean, this business has extremely high operating margins. I don't know if you're willing to comment on that, or I assume maybe you'll give us more information when you actually close the deal.
Karen Burton
executiveYes. Mike, this is Karen; we will give updated guidance once we close the deal. Certainly, we expect it to be accretive top to bottom, revenue, margins, and EPS. But I would encourage you to make sure you're including all of the interest costs, as we are funding this deal with debt.
Mike Matson
analystAlright, so basically we had figured on an interest rate of about 6%. Is that roughly in the right range?
Karen Burton
executiveThat's definitely correct.
Mike Matson
analystOkay. All right. Back in September, at an investor conference, somebody made some remarks about customers destocking in the AST business. I believe you've sort of handled that already by mentioning things improved in October, but I just wanted to see whether you could expand on those remarks a little? Thanks.
Dan Carestio
executiveYeah, sure, Mike. Thanks. Yeah, I think we're at a point where we can say with confidence that destocking is over. Our belief is that it washed itself out during the quarter we just finished. After that, at the back end of the quarter, we saw growth return to a more normalized level; then October brought pretty good revenue growth, which we normally don't hit on, but since it's relevant to what we've been saying for the last six months — that the first half's going to be tough; then we got easier comps in the second — we're confident in delivering that message.
Mike Matson
analystOkay, thank you.
Dan Carestio
executiveYep.
Jason Bednar
analystHey there. Morning, everybody. Appreciate the questions. I'll take one on AST; it follows up a bit on a few other questions; to be clear, there's no change to the growth guidance here, it comes down to somewhat softer procedure volumes, I believe. Could you sharpen what you expect in the guidance regarding volume growth for your U.S. and European customers? Are you assuming the stronger volume growth, the stronger business performance you mentioned, Dan, in September and October, carries on through the remainder of your fiscal year? Or how sensitive is it to improvement or softening from here, given the macro still carries a layer of uncertainty?
Dan Carestio
executiveYeah. Jason, honestly, thanks for asking. It's fairly straightforward math. What I mean is, in last year's first half, the period we're comparing against, we grew more than 10%. Then that decelerated markedly, if you look back at the constant currency organic figures, to mid to low single digits. The comps and growth simply get much easier to reach once we began seeing destocking in last year's third quarter. Because of that, and given what we view as a very stable Healthcare operating environment at present, we're confident that against those easier comps, we ought to deliver far higher than we did in the first half.
Jason Bednar
analystOkay. Perhaps one quick follow-up on that, and after that I have another question. I believe many investors are genuinely attempting to get their heads around the sell-in versus sell-out picture — what you are observing — and I understand that you sit a layer back from sell-out, so to speak, from the real procedure volumes. So, are you noticing anything different that is shifting simply because plenty of information is circulating out there pointing to somewhat softer volumes? I suppose, once more, just trying to figure out whether there is anything to it. Then my other question, and maybe this one is for you, Karen. Could you discuss what has prompted yet another restructuring program? From a strategic standpoint, it feels like these have perhaps grown somewhat more frequent over the last few years. Is anything changing in terms of how you approach operations and your portfolio?
Dan Carestio
executiveYes. Thank you, Jason. I will begin with your question about volumes. You used the phrase softer volumes, and in my view that is greatly overplayed. The reality is that certain highly elective procedures have been deferred and will be deferred. A number of our peers in various segments of highly elective products have spoken about that. Some have even contradicted one another regarding what they are observing. I think that is simply where things stand at present. There is still strong growth occurring in Healthcare when it comes to general procedures. I have said, and I have been clear, that it sits at the low end of the range — meaning that if we typically assume a procedure growth rate somewhere between 2.5%, 3%, and 5%, particularly for North America, we are likely down around 3% at the moment. But it remains a growth rate, correct. It is not negative or flat. We have an enormous amount of data from all the SPDs, sterile processing departments, that we operate throughout North America and the U.K; and other locations in Europe indicating that tray numbers and consumption are up. From everything we are examining, even though our customers clearly face economic stress, especially in North America, demand is still at a high level.
Karen Burton
executiveOkay, Jason. I'll spend a moment on restructuring. This new plan focuses on a handful of smaller moves. Those would involve several main pieces, such as dropping a single-use urology scope from the portfolio we offer. The costs tied to it cover inventory disposal, ending supply contracts, and impairment of intangible assets. Another main piece involves consolidating a few small sites, which includes moving production of our sterility assurance products to the new Mentor manufacturing site that was announced early in fiscal 2026. The plan we announced in August, alongside the announcement of the Formulated Chemistry Center of Excellence, was entirely centered on that action and on the impact of that center of excellence. We deliberately kept these other actions separate, so it would be clear what we were doing and when those actions would occur. As you mentioned, this is somewhat unusual for us. We have two announced this year; we had the Bordeaux restructuring a couple of years back now. I would say that, taken together, what you are seeing is a focus on genuinely challenging our portfolio along with our manufacturing and distribution network, and that is the main force behind all three of these plans.
Jason Bednar
analystOkay, thanks to you both.
Mike Polark
analystAppreciate you taking the follow-up. One more question on Life Sciences. Dan, I did hear what you said about one big order worth $10 million, that came through loud and clear, but the segment grew 18%, and capital was up 50%. So something was working well. You mentioned onshoring and localization of supply chains. Understood. We all know that is a mega trend. That said, I'd characterize the feedback out of bioprocessing, just as one example, as somewhat mixed and still pretty slow-going. What I want to ask is whether you think there might be something else at play here, and the other topic in tools land is these so-called self-driving labs now that Claude is starting to do experimentation. My joke is that Claude will get the beakers dirty as well, and then somebody has to clean them. Do you see any evidence that a theme like that presents an opportunity for Life Sciences beyond reshoring? Thank you.
Dan Carestio
executiveThanks, Mike. Yes, clearly we do view that as an opportunity. What I'd say is that it isn't registering yet in our order book or anything along those lines. As that trend continues, I believe the way aseptic pharmaceuticals get produced will shift over time, and I believe STERIS will be well positioned to adapt to that. What I think we're seeing in Life Sciences order intake and shipments on the capital side is partly some pent-up demand from a couple of years of under-buying in the pharmaceutical sector, and now there's a bit of catch-up happening. So we're benefiting from that.
Mike Polark
analystThanks.
Julie Winter
executiveI appreciate everyone joining us this morning to hear more about the quarter and what we expect for the year. We’ve got a fair number of conferences on the calendar this fall. Hope to see plenty of you out on the road.
Operator
operatorThat brings us to the end of this conference. We appreciate your joining the presentation today. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete STERIS plc transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to STERIS plc earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in STERIS plc or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.